Aim
A collaborative platform to support analysis and machine workloads to support its ongoing research into next generation vaccines for cancer and a variety of infectious diseases.Challenges
- →Massive compute requirements.
- →Extensive machine learning (ML) workloads.
- →Requirements to run on-premises and in the cloud.
- →Need for reproducible auditable workflows.
We are excited about the direction the Seqera team is taking their solutions and are looking forward to playing our part in advancing this technology for the industry as a whole.
— Michael Kroell, Director Cloud Engineering
Solution
Nextflow
Efficiently dispatch data pipeline and machine-learning workloads.
Seqera
Monitor, manage, and share pipelines and dynamically provision and manage AWS resources efficiently.
AWS Batch
Deploys appropriate CPU and GPU-based resources as they are required by researchers via its integration with AWS Batch.
Results
- →Increased capacity. By using fast, high-throughput Nextflow pipelines that maximize parallelism, Gristone has been able to boost their research productivity. By using AWS Batch they can efficiently access the latest cloud-based GPU instances and pay for only the resources they need
- →Improved collaboration. With Seqera Workspaces, Gritstone has been able to segment their pipelines, datasets, and compute environments around their various research efforts and clinical trials for candidate vaccines. By controlling access to pipelines, runs, and data via rich role-based access controls (RBAC), Gristsone is able to facilitate sharing while protecting sensitive information and intellectual property.
- →Reliable, repeatable, auditable workflows. Nextflow and Seqera’s close integration with popular source code managers (SCMs) means that researchers can run different versions of analysis pipelines directly from code repositories with an auditable history of all runs and results.
- →Reduced cloud spending. By using AWS Batch to support computational requirements for analysis and ML pipelines, Gritstone have avoided the cost and complexity of deploying additional HPC resources on-premises.
About
Gritstone bio is developing next-generation vaccines for cancer. Gritstone’s approach seeks to generate potent and durable immune responses by leveraging insights into the immune system’s ability to recognize and destroy diseased cells by targeting select antigens.
Trusted by Pharma to Deliver Reproducible Results at Enterprise Scale